Cargando…

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Murphy, ML, Chan, SKW, Bazley, L, Hayes, NVL, Gullick, WJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300282/ http://dx.doi.org/10.1186/bcr1590

Ejemplares similares

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2008)

Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines
por: Cui, Hai, et al.
Publicado: (2014)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

Pattern of expression of c-erbB-2 oncoprotein in human fetuses.
por: Quirke, P., et al.
Publicado: (1989)

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins
por: Smith, B L, et al.
Publicado: (2004)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

c-erbB-2 expression in benign and malignant breast disease.
por: Gusterson, B. A., et al.
Publicado: (1988)

An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
por: Barnes, D. M., et al.
Publicado: (1988)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
por: Schillaci, Roxana, et al.
Publicado: (2012)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
por: Lovekin, C., et al.
Publicado: (1991)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
por: Goren, D., et al.
Publicado: (1996)

An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.
por: Walker, R. A., et al.
Publicado: (1989)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
por: Doyle, Hester A., et al.
Publicado: (2021)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members
por: Olayioye, Monilola A
Publicado: (2001)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
por: Benlimame, Naciba, et al.
Publicado: (2005)

c-erbB-4 protein expression in human breast cancer
por: Kew, T Y, et al.
Publicado: (2000)

Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer.
por: Lemoine, N. R., et al.
Publicado: (1991)

HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
por: Khan, A N, et al.
Publicado: (2006)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Expression of HER2/c-erbB-2, EGFR Protein in Gastric Carcinoma and its Clinical Significance
por: Cheng, Guoxiong, et al.
Publicado: (2019)

Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and ErbB-2 Receptors
por: Oh, Yoon Sin, et al.
Publicado: (2011)

Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
por: Singer, Josef, et al.
Publicado: (2012)

Quantitative Analysis of ErbB1 and ErbB2 Genes Amplification by a High Performance Liquid Chromatography
por: Rasti, Mozhgan, et al.
Publicado: (2014)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2q3a0ir98f6mhknu4126fnghgh